|Bid||40.50 x 100000|
|Ask||40.80 x 100000|
|Day's Range||40.70 - 41.40|
|52 Week Range||30.65 - 47.50|
|PE Ratio (TTM)||16.16|
|Forward Dividend & Yield||0.40 (0.96%)|
|1y Target Est||N/A|
Mar.02 -- Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets."
Feb.01 -- Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses what he calls "strong momentum" for the company, the impact of the U.S., tax cut, and their M&A outlook after being outbid for Ablynx. He speaks with Bloomberg's Matt Miller on “Bloomberg Markets: European Open.”
Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets." (Source: Bloomberg)
A $165 million (£119 million) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines. Backed by Novo Holdings, which has big stakes in Danish drugmaker Novo Nordisk and enzymes specialist Novozymes, the new Repair Impact Fund will invest $20-40 million a year over three to five years in about 20 projects in Europe and the United States. Novo said on Wednesday its new fund would invest in start-ups, early-stage companies and corporate spin-outs, either as the sole investor or in a syndicate.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the biggest movers in the biotechnology sector this week on the news that the company has entered into a partnership with Kite, a company that’s owned by Gilead Company (NASDAQ:GILD). The deal comes on the back of a spate of fresh biotechnology deals that have hit press over […] The post Today’s Biotech Movers: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) And Novo Nordisk A/S (ADR) (NYSE:NVO) appeared first on Market Exclusive.
The world's largest diabetes drugmaker Novo Nordisk on Thursday presented the first successful data from a final-stage study for a pill it hopes will transform the diabetes market. The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure has been mounting in a crowded market targeting the world's 450 million diabetics. Novo Nordisk said the first of 10 phase III trials were successful in its primary objective by demonstrating "significant and superior" improvements in long-term blood sugar compared to a placebo.
Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.
After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill. Novo's oral semaglutide medicine is important for ensuring the group's long-term growth - a critical mission after 2017 results last week revealed mounting price pressure in a crowded market targeting the world's 450 million diabetics. Rivals, especially Eli Lilly, are watching Novo's final-stage oral semaglutide trials closely, ahead of the drug's potential 2020 launch.
The company "had the need to expand our current capability at the facility," says Chad Henry, corporate vice president and general manager of Novo Nordisk in Clayton. "As our patient base continues to grow … we hope that we can expand in the future," Henry says. Chris Johnson, director of Johnston County Economic Development, says he believes Johnston County was selected again by Novo Nordisk for the new expansion because of the county's commitment to workforce development and its existing relationship with the Denmark-headquartered company.
European stock gauges trade lower Thursday, falling for a fourth session in a row as global bond yields extend their recent climb.
The Bagsvaerd, Denmark-based company said it had profit of 53 cents per share. The drugmaker posted revenue of $4.43 billion in the period. For the year, the company reported profit of $5.79 billion, or ...
Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.
Novo Nordisk's chief executive welcomes that Amazon.com Inc, Berkshire Hathaway Inc and JPMorgan Chase & Co, has established a new company to cut health costs for their employees. Lars Fruergaard Jorgensen ...
Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.